Clinical evaluation demonstrates anti-CD7 CAR-T cell activity against central nervous system leukemia in T-ALL/LBL, highlighting potential strategies to overcome refractory disease.
Key Points
To assess the efficacy, safety, and trafficking kinetics of naturally selected anti-CD7 CAR-T cell therapy in patients with T-ALL/LBL involving the central nervous system.
Evaluated CD7-targeted chimeric antigen receptor T-cell administration in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma and central nervous system involvement.
Tracked CAR-T cell migration across the blood-brain barrier to determine clearance of central nervous system leukemia and monitored associated neurotoxicity.
CD7-targeted CAR-T cell therapy yields complete remission rates approaching 90% in relapsed or refractory T-ALL/LBL.
CAR-T cells demonstrate the capacity to traffic into the central nervous system and target leukemic cells while allowing characterization of treatment-related neurotoxic effects.